

Index

- a**
- actinides 160
 - albumin 318, 319, 476, 567
 - Alzheimer's diseases 395
 - AMBER 67, 70, 89, 90, 340, 513, 516, 517
 - ambiguous distance restraints 527, 534, 539, 540, 551, 554
 - ambiguous interaction restraint (AIR) 527, 529
 - amyloids 396, 397, 398, 402, 403
 - ASCAN 543, 544
 - antioxidant protein 1 (Atx1) 144, 145, 196, 198–200, 202, 432
 - ATNOS 381, 542–546
 - atomic force microscopy (AFM) 422
 - ATP 14, 50, 318–321, 326, 505
 - AutoAssign 513
 - automated projection spectroscopy (APSY) 544, 545
- b**
- bacteriorhodopsin 37, 372, 373, 411
 - BEST experiment 84, 148, 453, 454
 - β-hairpin 12, 14
 - biochemical pathways, in terms of mechanisms 3
 - biological magnetic resonance data bank (BMRB) 57, 86, 188, 378, 379, 383
 - 1,3-bisdiphenylene-2-phenylallyl (BDPA) 430
 - bovine pancreatic trypsin inhibitor (BPTI) 377
 - bovine spongiform encephalopathy (BSE) 396
 - β-bulge 12, 13
 - β-sheets 8, 9, 11, 12, 15–18, 38, 59, 61, 194, 396, 402–404
- c**
- CACO experiments 441
 - calmodulin 161, 168–170, 184, 185, 194, 208, 211
 - CANCOX/CANCOCA experiments 379
 - Carr–Purcell–Meiboom–Gill (CPMG) 50, 81, 92, 109, 268, 271, 277, 475
 - catabolite activator protein (CAP) 43, 241, 242, 487
 - CATH database 15
 - CBCACO experiments 441
 - ¹³C–¹³C correlation spectrum DARR spectra 397
 - ¹³C chemical shift dispersion 141, 148, 432, 435, 436, 439, 441
 - ¹³C direct detection 141, 142, 150, 163, 166, 199, 201, 245, 432, 433, 438, 442
 - cell-free 5, 179, 187, 244, 414, 496–508
 - chemically induced dynamic nuclear polarization (CIDNP) 410, 422
 - chemical shift 4, 35, 36, 38, 44, 55, 56, 58, 59, 61, 69, 71–74, 76–78, 80–84, 86, 88, 90, 92, 93, 94, 98, 100, 101, 103, 105, 106, 108, 109, 112, 113, 114, 122, 125–129, 131, 141–144, 148, 149, 151, 154, 156–158, 161, 162, 164, 165, 176, 177–181, 188, 189, 193, 201, 215, 222, 226, 231, 232, 243, 248, 258, 260, 262, 266, 288, 302, 303, 304, 307, 319, 320, 321, 326, 348, 349, 378, 383, 386, 390, 407, 412, 415, 435, 441, 483, 488, 513, 516, 538, 539, 542, 545, 560, 572
 - chemical shift anisotropy (CSA) 78, 79, 109, 127, 162, 184, 305, 349, 363, 369, 372, 374, 383, 384, 390, 407, 435, 556
 - chemical shift index (CSI) 56, 57, 61, 84, 86, 383
 - chemical shift perturbation (CSP) 44, 45, 174, 177, 180, 181, 199, 211, 212, 222, 223, 248, 261–263, 294, 301–303, 307–309, 411, 413, 489, 520, 523, 524, 555, 557, 558, 560
 - ChhC/NhhC experiments 387, 381, 416
 - cis/trans isomerization 42, 545
 - Collaborative Computing Project for NMR (CCPN) program analysis 398, 542
 - contact shifts 157–159, 206
 - continuous-exchange cell-free (CECF) 498, 499, 501, 505, 506
 - continuous flow cell-free (CFCF) 498
 - correlation spectroscopy (COSY) 53, 54, 101, 104, 111, 115, 223, 336, 337, 458, 552, 560
 - correlation time 42, 76, 78, 79, 122, 146, 162, 224, 424, 435, 459
 - Creutzfeldt–Jacob disease (CJD) 396
 - cross-correlated relaxation-enhanced polarization transfer (CRINEPT) 56, 190, 213, 222
 - cross-correlated relaxation-induced polarization transfer (CRIPT) 56
 - cross-β fibrils 403
 - cross-correlated-relaxation rates 374, 441
 - cross correlation 131, 162, 435, 548, 553
 - cross-polarization (CP) 127, 350, 351, 354, 357, 358–360, 379, 401, 417, 425, 426, 429
 - cross-saturation experiments 181, 223, 224, 248, 523, 524
 - cryo-electron microscopy 34–36, 35, 36, 242, 520, 526, 528
 - CS-ROSET TA 90, 513, 514, 531, 542
 - Curie and dipolar relaxation, cross-correlation between 162, 163
 - Curie relaxation 160, 162, 164, 214, 384
 - CYANA 66–68, 86, 87, 90, 166, 386, 403, 513, 514, 516, 517, 531, 540, 542
 - cyclophilin A (CYP A) 42
- d**
- DARR experiment see dipolar-assisted rotational resonance (DARR) 352, 353, 379–381, 387, 400, 401, 405, 416
 - DCP experiment 352, 357, 360, 361
 - 3D-DART 513, 529, 534
 - DEER (double electron-electron resonance) 208
 - deuterium 50, 76, 249, 368, 371, 372, 463, 524, 527, 565
 - DIANA 66
 - Dickerson–Drew dodecamer 48
 - differential line-broadening 181
 - diffusion anisotropy 523, 526, 528, 529
 - dihedral angles 8–14, 41, 59–61, 65–67, 75, 76, 87, 93, 128, 129, 164, 167, 191, 332, 333, 342, 388, 397, 412, 553, 573
 - RNA structure, restraint 128
 - scalar couplings 143
 - in structure calculation 59–61, 65–69, 87, 93
 - in validation of structures 72, 90
 - parameters encoding torsion angles 383
 - dihydrofolate reductase (DHFR) 43
 - DIPAP (double in-phase/antiphase) 437, 439
 - dip-shift spectroscopy 383, 384
 - dipolar-assisted rotational resonance (DARR) 352, 353, 379, 380, 381, 387, 400, 401, 405, 416
 - dipolar recoupling 351, 352, 354, 382–384, 389, 400, 409, 416, 417
 - dipolar recoupling enhanced by amplitude modulation (DREAM) 352, 353, 400
 - dipolar relaxation 162, 166, 178, 372, 426, 432
 - dipole–dipole interaction 113, 114, 126, 130, 158, 161, 351, 369, 407, 424, 426
 - dip-shift spectroscopy 382, 383
 - DISMAN 65
 - distance restraints 35, 38, 40, 58, 59, 65, 69, 93, 114, 180, 209, 228, 332, 333, 381, 383, 390, 434, 514, 528, 544, 551, 572
 - docking 44, 198, 202, 208, 214, 250, 520–534, 550, 554, 555, 560
 - DNA
 - folding topology 99, 100

- backbone conformation 105, 106
 - glycosidic torsion angles 98
 - heteronuclear experiments 106, 107
 - oligonucleotides 97
 - pentofuranosyl moiety 98
 - pseudorotation of deoxyribofuranose rings 104, 105
 - resonance assignment 100–104
 - DNA recombination 48
 - DNA–RNA hybrids 25, 31, 32
 - DNA structure 24–27, 48, 96, 103, 108, 111, 247, 288
 - DOTA 64, 188
 - DOTP 182
 - DREAM 352, 353, 400
 - DTPA 182, 183, 187–189, 190, 193, 194, 225
 - dynamic frequency shift (DFS) 410, 422, 423, 426, 427, 428, 429, 430
 - dynamic nuclear polarization (DNP) 410, 420–431
 - dissolution DNP 429, 431
 - HF liquid DNP 427–430
 - shuttle DNP 428, 430
 - chemically induced (CIDNP) 410, 422
 - dynamics, in proteins 41–43, 76–83, 176, 177, 208–211
 - dynamics, in proteins at the solid state 367–375
- e**
- EBURP 460
 - echo-planar imaging (EPI) 454
 - ECOSY 104, 105, 112
 - electron Bohr magneton 157
 - electron microscopy (EM) 175, 186, 501, 572
 - electron paramagnetic resonance (EPR) 187, 206, 208, 213, 225, 385, 410, 412, 423, 424, 425, 429, 430
 - electron relaxation 136, 156, 157, 160, 163, 385, 424
 - ENDOR 427
 - Enterococcus faecalis 36
 - Ernst angle excitation 451, 453, 454
 - Escherichia coli* 30, 120, 133, 229, 230, 243, 398, 414, 480, 481, 490, 498, 499, 507
 - expression system 499
 - exchange transferred nuclear Overhauser effect spectroscopy (et-NOESY) 331
 - EXAFS 202
 - exchange spectroscopy (EXSY) 82
- f**
- fast N-dimensional NMR 447, 457–463
 - fibrillization 397, 398, 402
 - fibrils 5, 37, 394–404
 - fluorescence correlation spectroscopy 50
 - fluorescence polarization (FP) 322, 323
 - fluorescence resonance energy transfer (FRET) 50, 186, 322, 572
 - fluorine labeling 304, 305
 - fluorine atoms for biochemical screening (FABS) 317–319, 322, 325, 326
 - fluorine NMR spectroscopy 314–326
 - folding topology of DNA 99, 100
 - folds of proteins 15–18
 - force field (FF) 40, 66, 67, 70, 75, 129, 148, 250, 333, 341, 381, 541, 550, 554
 - Fourier transform 115, 369, 421, 476, 566
 - fragment-based drug design (FBDD) 254–263
 - Fremy's salt 420
- FRET (fluorescent resonance energy transfer) 50, 186, 322, 572
- Fusarium oxysporum 16
- g**
- Golgi apparatus 413
 - G-protein-coupled receptors (GPCRs) 411
 - G-quadruplex 26, 27, 48, 50, 96, 105, 107, 110, 113
 - Greek key motif 14, 16, 17
 - green fluorescent protein (GFP) 509
 - grid infrastructure 511, 512–516
 - Guinier plot 564, 567
- h**
- HADDOCK 44, 201, 214, 250, 513, 514, 520, 523–534
 - Hartman-Hahn condition 359, 360
 - α -helices 10, 11, 13, 15, 17, 19, 59, 329, 384
 - hemoglobin 8, 16
 - heteronuclear decoupling 351, 354, 360, 370, 408, 454
 - HETLOC 336, 338, 339
 - HET-s 352, 394, 397–399, 400, 401, 403, 404, 463
 - ¹H-flip method 441
 - high-throughput screening 255–263, 422, 484, 552
 - HiPIP 161
 - HMBC 49, 106, 334, 335, 339, 477
 - HMQC 101, 106, 142, 222, 439, 454, 460, 464, 465 ¹H–¹⁵N heteronuclear single-quantum coherence (HSQC) spectrum 35, 36, 44, 79, 81, 83, 85, 93, 100, 110, 143, 154–156, 165, 169, 183, 190, 200, 201, 202, 222, 289, 292, 294, 302, 483, 487–491, 525, 544, 560,
 - HOESY 305
 - homonuclear decoupling 436–439
 - homonuclear recoupling schemes 353, 354
 - HORROR 352, 353
 - HPLC 134, 135, 471
 - human immunodeficiency virus (HIV)-1 225, 299, 301, 309, 318, 368
 - hyperfine shift 157–161, 185, 434
- i**
- ILOE 259, 267, 273, 274, 278, 279
 - imino–proton resonances 100
 - INADEQUATE 355
 - in-cell protein NMR spectroscopy 479–493
 - post-translational modification 138, 152, 484, 485, 491, 492
 - INPHARMA 267, 268, 274, 553
 - in-phase/antiphase (IPAP) 213, 436
 - insensitive nuclei enhanced by polarization transfer (INEPT) experiments) 106, 191, 351, 375, 385, 401, 421, 453
 - integral membrane proteins (IMPs) 497
 - intrinsically disordered protein (IDP) 137–152, 432
 - ion channels 411, 412
 - ITC 272, 277, 279, 280
- j**
- ³J couplings 60, 332, 333, 337–339
 - jelly roll motif 17
- k**
- Karplus–Altona equation 104
 - Karplus-type relationships 143, 158
 - KcsA-Kv1.3 373, 411, 412, 413, 416
 - Kratky plot 564, 567
 - kinase 318, 320, 322, 484, 491, 505, 553
- l**
- lanthanides 160, 164, 187, 205, 206, 504, 525, 551
 - lanthanide binding tag (LBT) 64, 168, 187, 555
 - Larmor frequency 78, 160, 163, 322, 385, 424, 430
 - laser-induced liquid bead ion desorption (LILBID) 501
 - Lee-Goldburg cross polarization 383
 - Lennard–Jones potential 66
 - ligand-observed NMR spectroscopy 265–282, 274, 305, 306
 - LILBID 501
 - lipid based cell-free 499
 - LOGSY 268, 270, 276, 305, 551, 559
- m**
- magic angle spinning (MAS) 152, 346, 349, 350, 356, 357, 368, 371, 387, 388, 395, 407, 408, 411, 482
 - magnetic moment 36, 56, 61, 137, 157, 158, 160–162, 185, 273, 434
 - magnetic resonance imaging (MRI) 249, 421, 454, 480
 - magnetic susceptibility 61, 114, 156, 162, 163, 164, 370
 - Maigh–Mallion theory 556
 - maltose binding protein (MBP) 169, 193
 - MARS 513, 514
 - mass spectrometry 213, 216, 234, 257, 293, 501, 526
 - matrix metalloproteinase (MMP) 14, 36, 92, 352, 385–388, 390, 391
 - McConnell equations 176
 - MDDNMR 513, 514
 - membrane proteins 4, 5, 37, 43, 372, 406, 408, 413, 414, 497, 499, 501, 502, 506, 507, 565
 - biogenesis 413
 - cell-free expression 498, 499
 - solid-state NMR studies of 408–413
 - messenger RNA (mRNA) 32, 50, 218, 230, 239, 299, 505, 506
 - metabolomics, in systems biology 5, 467–477
 - metal ions 163, 164
 - met-aquomyoglobin 164
 - metallodrugs, and DNA interactions 283
 - coordinative binding 284–289
 - dual binding 291
 - with π -bonded intercalator 292, 293
 - with σ -bonded intercalator 291, 292
 - groove binding 289, 290
 - intercalation, and insertion 290, 291
 - metal-mediated interactions 197–203
 - Mia40 protein 19
 - microRNAs (miRNAs) 50
 - MIRROR 352, 353, 400, 401
 - model-free 79–82, 91, 369, 373
 - molecular dynamics (MD) 66, 78, 250, 331, 381, 411, 516, 540, 570
 - molecular fragment replacement (MFR) 71, 379, 383
 - Mossbauer spectroscopy 368
 - M2 proton channel 37

- multidimensional NMR 53, 85, 96, 149, 445–465
 MaxEnt processing 450, 458, 459
 myoglobin 16
- n**
 NCACB experiment 354, 399, 401, 415
 NCACO experiment 398–400
 NCACX experiments 415
 NCA/NCO experiments 379
 NMR bundle 37–41, 394
 NOESY experiment 54–57, 59, 73, 74, 87, 93, 94, 103, 113, 223, 259, 294, 310, 311, 312, 336, 432, 536, 544, 550, 552, 539, 544, 560
 – automated NOESY assignment 69
 nuclear Overhauser effect (NOE) 39, 48, 58, 59, 79, 98, 106, 123, 126, 127, 161, 180–181, 295, 304, 308–311, 331, 371, 380, 381, 435, 524, 539, 545, 546, 538, 539, 550, 552, 555
 – assignments 180, 538, 539, 545, 550
 – connectivities 54, 101, 111, 294
 – heteronuclear NOE 145, 374, 382
 – intermolecular NOE 202, 228, 242, 263, 310, 523, 524, 527, 552
 nucleic acids 21–32, 47–50
 – conformations 22–24
 – G-quadruplex structures 48
 – nuclear Overhauser effect (NOE) pattern 48
 nucleosome 48
- o**
 omics sciences 468
 order parameter 40, 43, 65, 79, 80, 370, 374, 383
- p**
 PAIN 382, 401, 402
 PAR. *See* proton-assisted recoupling (PAR)
 paramagnetic cross-correlation (PCCR) 162
 paramagnetic effects 73, 128, 145, 156, 160, 194, 204, 208, 210, 212–214, 216, 384, 434, 525
 paramagnetic line broadening 163, 164
 paramagnetic relaxation enhancement (PRE) 128, 145, 154, 159–161, 163, 178, 206, 221, 301–303, 308, 384, 385, 434, 504, 524, 525
 – solvent PRE 178, 182, 183, 190, 191, 193
 paramagnetic tag 145, 156, 174, 186, 206, 212–214, 251, 523, 525
 paramagnetism-assisted NMR 154, 155, 156, 165–170
 paramagnetism-based drug discovery 164, 165
 PARIS (phase-alternated recoupling irradiation scheme) 352, 353
 PCS. *See* pseudocontact shift (PCS)
 PDS. *See* proton-driven spin diffusion (PDS)
 Pecosy 104, 105, 112
 Pichia pastoris 480
 PISEMA 348
 plasma 33, 468, 469, 473–477
 Podospora anserina 396, 404
 polarization transfer 400, 401
 polymers 98, 396, 408, 505
 Porod's law 567
 post-transcriptional regulation 219, 221
 potassium channel 373, 411–413
 PRDC 154, 159, 161, 162, 164, 166–170. *See also* residual dipolar couplings (RDCs)
 PRE. *See* paramagnetic relaxation enhancement (PRE)
 precipitate generating cell-free 499
- principal component 158, 471, 472
 prions 139, 396, 398, 399, 404
 PROCHECK 9, 75, 388
 propeller blade 17
 PROSA 92
 protein–DNA interactions 239–252
 protein–ligand complexes 549–561
 protein–protein complexes 19, 44, 175, 179–181, 185–193, 198, 199, 200, 201, 204–208, 250, 252, 374, 483, 521
 protein–RNA complexes 21, 50, 128, 219–235
 proteorhodopsin 43
 proton-assisted recoupling (PAR) 352, 354, 382, 401, 416
 proton-driven spin diffusion (PDS) 352, 353, 370, 371, 373, 379–382, 387, 388, 401, 416
 pseudocontact shift (PCS) 63, 128, 154, 157, 158, 159, 161, 164, 168, 178, 204, 206, 225, 384, 386, 390, 391, 416, 504, 523, 525, 548, 554, 555
 pseudorotation of deoxyribofuranose rings 104, 105
 PULCON 324, 325
 pulse sequences 93, 109, 180, 272, 276, 352, 363, 399, 401, 441, 453, 460
 – band-selective pulses 439, 440, 442
 – heteronuclear decoupling 347, 350, 351, 354, 360, 370, 408, 454
 – ligand-observed NMR spectroscopy 265, 274, 276
 – recoupling sequences 361, 362, 400
- q**
 quaternary structure 7, 8, 19, 566, 571
 – of multidomain proteins and complexes 177
 – rigid-body modeling of 568, 569
- r**
 radiofrequency-assisted diffusion (RAD) 380, 381
 radiofrequency-driven recoupling (RFDR) 352, 353, 381, 382, 385
 Ramachandran plot 9, 11, 13, 75, 90, 192, 193, 388
 RDCs. *See* residual dipolar couplings (RDCs)
 REBURP 460
 REDOR 382, 384
 relaxation rates 42, 78, 143, 145, 149, 159, 164, 181, 242, 336, 366–368, 372–374, 423, 425, 436, 441, 452, 453, 526
 residual dipolar couplings (RDCs) 38, 42, 50, 61–65, 78, 87, 127, 161, 162, 332, 333, 438, 504, 525, 526, 560, 569
 – paramagnetism-induced 161, 162
 resonance assignment 37, 53–58, 101–103, 188, 263, 330, 334–336, 378–380, 389, 398–400, 408, 415, 513, 538, 541–545
 – automated NOESY assignment 69, 86, 544
 retinal proteins 37, 411
 reversible membrane permeabilization 480
 rhodopsin 37
 ribosomal ribonucleic acid (rRNA) 27, 30, 299, 300
 riboswitches 50
 ribozymes 50
 ring current 108, 220, 222, 556, 557
 RNA as target for small molecules 299–312
 RNA
 – chemical synthesis 120, 121
 – dynamics 50, 119
 – fold 121, 122
 – quality of NMR structures 129
 – resonance assignment 123–126
 – spectral resolution 122, 123
 – structure 27–32
 – transcription 31, 50
 RNA-induced silencing complexes (RISCs) 50
 ROCSA 383
 ROE 331, 335, 337
 ROESY experiment 331, 336, 337, 340
 rotational echo double resonance (REDOR) 382
 rotor filling tool, for ultracentrifuge 398
- s**
 SANS. *See* small angle neutron scattering (SANS)
 SAS. *See* small angle scattering (SAS)
 saturation transfer 181, 223, 552, 554
 SAXS. *See* small angle X-ray scattering (SAXS)
 scattering pattern 564
 SCOP, structure classification database 15
 Scorpion toxin kaliotoxin (KTX) 412
 SDS-PAGE 484, 492, 493
 S^3E (spin-state-selective excitation) building block 437
 secondary structure elements 9–18
 self-orientation, RDC due to paramagnetism (PRDC). *See* residual dipolar couplings (RDCs)
 sensitivity 44, 55, 84, 149, 243, 274, 322, 384, 422, 438, 451, 454, 479, 481, 501
 – in solid state NMR 5, 37, 349, 352, 362, 363, 377, 380, 410, 411, 416
 – in solution 452
 sensory rhodopsin II (SRII) 411
 serum 318, 319, 468, 472, 473, 475
 simulated annealing (SA) 66–68, 167, 383, 392, 515, 550,
 single-protein production (SPP) method 414
 small angle neutron scattering (SANS) 168, 242, 564, 565, 569, 571
 small angle scattering (SAS) 168, 563–566, 569–574
 small angle X-ray scattering (SAXS) 564, 565, 569, 570
 small interfering RNAs (siRNAs) 50
 SMILI-NMR 484, 489–491
 SOFAST experiment 453, 454, 459
 Solomon equation 385, 423, 452
 SPECIFIC-CP 383, 415
 spectral density 78, 79, 82, 369, 370, 374, 424, 427
 spin diffusion 54, 55, 57, 101, 181, 305, 370, 371, 400, 429, 523, 524, 553
 spin label 168, 169, 174, 185, 186, 189, 194, 225, 233, 246, 271, 504, 566
 spin–orbit interactions 160
 spin polarization 421–422
 SPINAL 351, 379, 382
 STD experiments 269, 277, 304, 305, 553, 554, 559
 stereo-array isotope labeling (SAIL) 503
 STINT-NMR 483, 484, 487, 488, 491, 493
 Stokes–Einstein equation 42
 structure–activity relationship (SAR) 44, 257–259, 263
 sugar pucker 22, 23, 99, 105, 112, 127, 287
 superoxide dismutase (SOD) 8, 163, 385, 432
 surface plasmon resonance (SPR) 278
- t**
 TALOS 89, 383, 386–390, 514, 514
 TEDOR 378, 381, 382, 387, 388

- TEMPO 182, 225, 260, 271
TEMPOL 225, 428, 429
tertiary structure 8, 14, 18, 19, 35, 113, 329, 334, 565
thin layer chromatography (TLC) 133
third spin-assisted recoupling (TSAR) 382
TIM 17, 368, 372
time-resolved WAXS experiments 565
titration 50, 180, 211, 212, 230, 231, 262, 303, 312, 320, 483, 487, 531
transactivation response (TAR) 368
transferred echo double resonance (TEDOR) 382, 383
transient structures 109, 110
translational diffusion coefficients 107
transmembrane (TM) 408–411, 415, 502, 503
transverse Manfield-Rhim-Elleman-Vaughn (T-MREV) 383
total correlation spectroscopy (TOCSY)
 experiment 54, 101, 122, 193, 223, 303, 330, 451, 552
 transfer RNA (tRNA) 30, 120, 179, 299, 501
 transferred nuclear Overhauser effect (trNOE) 272, 305, 331, 548, 553
 transverse Manfield-Rhim-Elleman-Vaughn (TMREV) 383
 triosephosphate isomerase (TIM) 368
 T7 RNA polymerase 505
 TOCSY 54–57, 101, 102, 111, 115, 183, 303, 339, 451, 552, 560
 TROSY 56, 57, 125, 128, 208, 213, 215, 222, 244, 463, 501, 503
 truncation artifacts 115, 446
 TSAR. *See* third spin-assisted recoupling (TSAR)
- u**
ubiquitin 43, 352, 377, 440, 483, 484, 491, 492, 571
ultrafast MAS 354, 355, 359, 362, 384, 410
ultrafast two-dimensional NMR 454–457, 462, 463
UNIO 542–546
- Ure2p 13, 397, 401, 404, 405
urine 468–470, 473–477
C DARR spectra of 405
- w**
WaterLOGSY 265, 268, 270, 277, 326, 551, 552, 559
wide angle scattering (WAXS) 565
- x**
X-ray crystallography 21, 34, 35, 49, 175
XPLOR 66, 90, 166, 214, 250, 514, 531
- z**
Zeeman bath 426
Zeeman energy 157, 158, 423, 425
Zeeman splitting 426
zinc finger transcription factors 18
ZZ-exchange 50